MARKET

ARDX

ARDX

Ardelyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.55
-0.12
-2.12%
After Hours: 5.55 0 0.00% 16:00 09/23 EDT
OPEN
5.68
PREV CLOSE
5.67
HIGH
5.79
LOW
5.52
VOLUME
636.51K
TURNOVER
--
52 WEEK HIGH
8.82
52 WEEK LOW
4.157
MARKET CAP
494.73M
P/E (TTM)
-4.6650
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of tenapanor for
PR Newswire · 09/15 12:00
Ardelyx to Participate in Three Upcoming Investor Conferences in September
PR Newswire · 09/08 13:00
DISH, ARDX, BBQ and AHT among after-hours movers
Gainers: [[DISH]] +6.2%. [[ARDX]] +5.5%. [[CCH]] +5.1%. [[BBW]] +3.7%. [[LPRO]] +3.5%. Losers: [[BBQ]] -6.5%. [[FTSI]] -4.9%. [[LBTYK]] -4.3%. [[ABUS]] -4.3%. [[AHT]] -3.5%.
Seekingalpha · 08/28 21:51
Reflecting on Ardelyx's (NASDAQ:ARDX) Share Price Returns Over The Last Five Years
We think intelligent long term investing is the way to go. But no-one is immune from buying too high. To wit, the...
Simply Wall St. · 08/27 13:41
Ardelyx EPS misses by $0.02, beats on revenue
Ardelyx (NASDAQ:ARDX): Q2 GAAP EPS of -$0.28 misses by $0.02. Revenue of $1.84M (+9100.0% Y/Y) beats by $0.9M. Press Release
seekingalpha · 08/06 18:05
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -3.70% and 63.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 15:45
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today reported business highlights and financial results fo
PR Newswire · 08/06 12:00
Were Hedge Funds Right About Dumping Ardelyx Inc (ARDX)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 08/03 14:55
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARDX. Analyze the recent business situations of Ardelyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARDX stock price target is 13.00 with a high estimate of 15.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 157
Institutional Holdings: 85.49M
% Owned: 95.91%
Shares Outstanding: 89.14M
TypeInstitutionsShares
Increased
42
6.36M
New
46
839.07K
Decreased
29
6.20M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Michael Raab
Chief Financial Officer/Chief Accounting Officer
Justin Renz
Chief Administrative Officer
Elizabeth Grammer
Other
Susan Rodriguez
Other
David Rosenbaum
Independent Director
Robert Bazemore
Independent Director
William Bertrand
Independent Director
Geoffrey Block
Independent Director
Onaiza Cadoret-Manier
Independent Director
Jan Lundberg
Independent Director
Gordon Ringold
Independent Director
Richard Rodgers
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ARDX
Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ardelyx Inc stock information, including NASDAQ:ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.